Tag Archives: Drugs

10 Years of Legal Weed: Fewer Opioid Deaths, More Jobs and Tax Revenue

I got an interesting message in my e-mail this morning. The NPR Planet Money newsletter reviewed the prior nearly ten years in legal marijuana in some states, and came to some interesting conclusions:

What’s changed:

  • More marijuana use
  • Way more jobs
  • Way more tax revenue. California makes over $600 million a month.

What hasn’t:

  • No effect on crime or traffic accidents
  • No change in price of marijuana. Evidently the product and service at the legal stores is so good people prefer it to anything else.

What might have:

Use of opioids. In the working paper linked from the newsletter, I found this incredible stat:

…Chan, Burkhardt, and Flyr (2020) show that RMLs [recreational marijuana laws] reduce opioid mortality by 20% to 35%, implying that both opioid use and misuse decline as legal marijuana access expands.

Given the mass death caused by opioids, this alone seems like reason enough to legalize marijuana in my book.

I read this newsletter with particular interest since I live in New Jersey, which recently legalized marijuana but doesn’t yet have weed stores the way California, Colorado and other states do. It looks like we mostly have positive changes to look forward to.

For more posts on politics and news, check these out:

If you found this post interesting, please share it on Twitter/LinkedIn/email using the buttons below. This helps more people find the blog! And please leave a comment at the bottom of the page letting me know what you think and what other information you’re interested in!

Check out the Stuff I Use page for some great deals on products and services I use to improve my health and productivity. They just might help you too! 

Photo: “Vancouver Global Marijuana March 2015 – by Danny Kresnyak” by Cannabis Culture is licensed under CC BY 2.0

Has Merck Found the Cure for COVID?

Merck has come out with great results from a new drug for COVID:

Over the weekend, the Big Pharma and its biotech partner Ridgeback announced their drug, molnupiravir, hit one of its secondary objectives from a new trial, namely to reduce time to negativity of infectious SARS-CoV-2 virus isolation from swabs in patients with symptomatic COVID-19.

The data show that, at Day 5, there was a reduction in positive viral culture in subjects who received molnupiravir (all doses) compared to placebo: 0% (0/47) for molnupiravir and 24% (6/25) for placebo.

These findings are preliminary, and more data will come out soon:

This is just a peek, with primary endpoints and more secondaries “to be presented at an upcoming medical meeting,” which will show a much clearer picture of how well this drug may be working.

We should know a lot more within the next few weeks:

Data from the phase 2/3 pivotal studies of the med are expected this quarter.

This drug could be great for people who are hesitant to get a vaccine, who haven’t been able to get one yet, or for whom the vaccine did not prevent infection (rare but possible). Good news!

For more on COVID drugs and vaccines, check out these posts:

If you found this post interesting, please share it on Twitter/LinkedIn/email using the buttons below. This helps more people find the blog! And please leave a comment at the bottom of the page letting me know what you think and what other information you’re interested in!

Check out the Stuff I Use page for some great deals on products and services I use to improve my health and productivity. They just might help you too! 

Photo: Merck CEO Kenneth Frazier, “File:Kenneth C. Frazier.jpg” by Merck (www. Merck.com) is licensed under CC BY-SA 3.0